BRAF and colonic neoplasm: MSI‐H or TMB‐H samples were significantly more abundant in the RAS/BRAF‐altered subset in both colon and rectal cancer: In the RAS/BRAF‐wt subset, 4.5% were MSI‐H and 7.8% TMB‐H, whereas in the RAS/BRAF‐altered subset 7.1% were MSI‐H and 10.6% TMB‐H in colon cancer (P < 0.001, Fisher's exact test, Figs S3C, S4C).